Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company that focuses on developing innovative medicines for central nervous system disorders. The company is known for its research and development efforts, led by key figures like Craig C. Hopkinson, who recently sold 9,000 shares at $30.38 each. Despite this sale, Hopkinson still holds 69,740 shares, reflecting his continued investment in the company.Alkermes is making strategic moves to expand its portfolio, as seen in its recent acquisition deal with Ava ...